Enzymatic Characterization of Wild-Type and Mutant Janus Kinase 1

Enzymatic Characterization of Wild-Type and Mutant Janus Kinase 1

Janus kinases (JAKs) are found constitutively associated with cytokine receptors and are present in an inactive state prior to cytokine exposure. Activating mutations of JAKs are causative for a number of leukemias, lymphomas, and myeloproliferative diseases. In particular, the JAK2<sup>V617F&...

Full description

Bibliographic Details
Main Authors:	Nicholas P. D. Liau, Artem Laktyushin, Rhiannon Morris, Jarrod J. Sandow, Nicos A. Nicola, Nadia J. Kershaw, Jeffrey J. Babon
Format:	Article
Language:	English
Published:	MDPI AG 2019-11-01
Series:	Cancers
Subjects:	jak jak/stat myeloproliferative disease v617f
Online Access:	https://www.mdpi.com/2072-6694/11/11/1701

Similar Items

JAK2V617F Allele Burden Measurement in Peripheral Blood of Iranian Patients with Myeloproliferative Neoplasms and Effect of Hydroxyurea on JAK2V617F Allele Burden
by: Shirin Ferdowsi, et al.
Published: (2016-04-01)

The C allele of <it>JAK2 </it>rs4495487 is an additional candidate locus that contributes to myeloproliferative neoplasm predisposition in the Japanese population
by: Ohyashiki Junko H, et al.
Published: (2012-01-01)

Splenomegaly in myelofibrosis—new options for therapy and the therapeutic potential of Janus kinase 2 inhibitors
by: Randhawa Jasleen, et al.
Published: (2012-08-01)

Identification of Novel Small Molecule Ligands for JAK2 Pseudokinase Domain
by: Anniina T. Virtanen, et al.
Published: (2023-01-01)

JAK2-V617F Mutation Combined with Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia: a Case Report
by: Farhad Shaveisi Zadeh, et al.
Published: (2011-04-01)

JAK2-V617F Mutation Combined with Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia: a Case Report
by: Mehrdad Payande, et al.
Published: (2011-06-01)

A newly identified 45‐kDa JAK2 variant with an altered kinase domain structure represents a novel mode of JAK2 kinase inhibitor resistance
by: Sivahari Prasad Gorantla, et al.
Published: (2024-02-01)

Transient ischemic attacks as the first presentation of JAK2-V617F positive chronic myeloproliferative neoplasm
by: Fani Kalala, et al.
Published: (2012-06-01)

Rapid, low cost and sensitive detection of Calreticulin mutations by a PCR based amplicon length differentiation assay for diagnosis of myeloproliferative neoplasms
by: Ngo Tat Trung, et al.
Published: (2019-06-01)

The Association Between JAK2V617F Mutation and Bone Marrow Fibrosis at Diagnosis in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms
by: M. Cem Ar, et al.
Published: (2012-08-01)

Evaluation of JAK2V617F mutation patients with non-CML myeloproliferative neoplasms by ARMS-PCR
by: F Nadali, et al.
Published: (2008-12-01)

Association of JAK2V617F mutation with thrombosis in Indian patients with Philadelphia negative chronic myeloproliferative neoplasms
by: Kanwaljeet Singh, et al.
Published: (2018-01-01)

Efficacy of WWQ-131, a highly selective JAK2 inhibitor, in mouse models of myeloproliferative neoplasms
by: Huan Ge, et al.
Published: (2022-12-01)

Clinical Impact of JAK2V617F Allele Burden in Philadelphia-Negative Myeloproliferative Neoplasms
by: İpek Yonal Hindilerden, et al.
Published: (2023-08-01)

Laboratory-developed Droplet Digital PCR Assay for Quantification of the JAK2<sup>V617F</sup> Mutation
by: Yupeng Liu, et al.
Published: (2024-06-01)

The Association between Prevalence of JAK2V617F Mutation and Blood Indicies in Groups of Patients with Myeloproliferative Neoplasms in Rasul Akram Hospital
by: Mohsen Razavi, et al.
Published: (2011-10-01)

The Association between Prevalence of JAK2V617F Mutation and Blood Indicies in Groups of Patients with Myeloproliferative Neoplasms in Rasul Akram Hospital
by: Akram Asghari, et al.
Published: (2011-12-01)

Clinical features of essential thrombocythemia and primary myelofibrosis, depending on the molecular characteristics of disease
by: A L Melikyan, et al.
Published: (2017-07-01)

The Role of LNK (SH2B3) in the Regulation of JAK-STAT Signalling in Haematopoiesis
by: Rhiannon Morris, et al.
Published: (2021-12-01)

Insights into the Potential Mechanisms of JAK2V617F Somatic Mutation Contributing Distinct Phenotypes in Myeloproliferative Neoplasms
by: Panhong Gou, et al.
Published: (2022-01-01)

Janus kinase V617F mutation detection in patients with myelofibrosis
by: Nikolova D, et al.
Published: (2019-08-01)

Chorea and Cognitive Impairment in JAK2V617F-Positive Myeloproliferative Disorders: A Case Report and Literature Review
by: Ioana Butnariu, et al.
Published: (2023-12-01)

Impact of CALR and JAK2V617F Mutations on Clinical Course and Disease Outcomes in Essential Thrombocythemia: A Multicenter Retrospective Study in Turkish Patients
by: Zehra Narlı Özdemir, et al.
Published: (2024-03-01)

Hip and Knee Osteoarthritis in Patients with Chronic Myeloproliferative Neoplasms: A Cross-Sectional Study
by: Hrvoje Holik, et al.
Published: (2023-06-01)

The role of FasR/FasL system in pathogenesis of myeloprolyferative neoplasms
by: Spasovski Vesna, et al.
Published: (2010-01-01)

A remarkable hematological and molecular response pattern in a patient with polycythemia vera during combination therapy with simvastatin and alendronate
by: Anders Lindholm Sørensen, et al.
Published: (2016-01-01)

A Murine Model With JAK2V617F Expression in Both Hematopoietic Cells and Vascular Endothelial Cells Recapitulates the Key Features of Human Myeloproliferative Neoplasm
by: Haotian Zhang, et al.
Published: (2021-10-01)

Diagnosis of latent polycythemia vera: A clinician’s opinion
by: A L Melikian, et al.
Published: (2016-07-01)

Mutational analysis of the Janus kinase II (V617F) gene in patients with β-Thalassemia major
by: Salar Adnan Ahmed
Published: (2020-12-01)

Evaluation of the JAK2V617F mutational burden in patients with philadelphia chromosome negative myeloproliferative neoplasms: A single-center experience
by: Popova-Labachevska M, et al.
Published: (2019-12-01)

STAT5 is Expressed in CD34<sup>+</sup>/CD38<sup>−</sup> Stem Cells and Serves as a Potential Molecular Target in Ph-Negative Myeloproliferative Neoplasms
by: Emir Hadzijusufovic, et al.
Published: (2020-04-01)

Translocation t(3;12)(q26;q21) In Jak2V617F Point Mutation Negative Chronic Idiopathic Myelofibrosis: A Case Report
by: S. Mešanović, et al.
Published: (2014-06-01)

Comparisions of ARMS-PCR and AS-PCR for the Evaluation of JAK2V617F Mutation in Patients with non-CML Myeloproliferative Neoplasms
by: Parisa Karimzadeh, et al.
Published: (2010-04-01)

Comparisions of ARMS-PCR and AS-PCR for the Evaluation of JAK2V617F Mutation in Patients with non-CML Myeloproliferative Neoplasms
by: Parisa Karimzadeh, et al.
Published: (2010-06-01)

THE ROLE OF JAK2 MUTATION IN THROMBOTIC COMPLICATIONS OF CHRONIC MYELOPROLIFERATIVE NEOPLASMS
by: Viola M. Popov, et al.
Published: (2014-08-01)

JAK2 V617F prevalence in Brazilian patients with polycythemia vera, idiopathic myelofibrosis and essential thrombocythemia
by: Bárbara da Costa Reis Monte-Mór, et al.
Published: (2007-03-01)

A mutação JAK2 V617F e as síndromes mieloproliferativas JAK2 V617F mutation and the myeloproliferative disorders
by: Bárbara C. R. Monte-Mór, et al.
Published: (2008-01-01)

Cell competition between wild-type and JAK2V617F mutant cells prevents disease relapse after stem cell transplantation in a murine model of myeloproliferative neoplasm
by: Haotian Zhang, et al.
Published: (2021-10-01)

Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations
by: Blum S, et al.
Published: (2016-09-01)

JAK2V617F Mutation Promoted IL-6 Production and Glycolysis via Mediating PKM1 Stabilization in Macrophages
by: Rongqing Li, et al.
Published: (2021-02-01)